O
Otto C. Boerman
Researcher at Radboud University Nijmegen
Publications - 358
Citations - 17532
Otto C. Boerman is an academic researcher from Radboud University Nijmegen. The author has contributed to research in topics: Radioimmunotherapy & In vivo. The author has an hindex of 66, co-authored 355 publications receiving 15882 citations. Previous affiliations of Otto C. Boerman include Radboud University Nijmegen Medical Centre.
Papers
More filters
Journal ArticleDOI
Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues.
Edgar J. Rolleman,Marleen Melis,Roelf Valkema,Otto C. Boerman,Eric P. Krenning,Marion de Jong +5 more
TL;DR: Future perspectives on improving kidney protection during PRRT include combinations of agents to reduce renal retention of radiolabelled peptides, eventually together with mitigating medicines.
Journal ArticleDOI
Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients
Floor C. J. van de Watering,Mark Rijpkema,Lars Perk,Ulrich Brinkmann,Wim J.G. Oyen,Otto C. Boerman +5 more
TL;DR: The production of 89Zr, the bioconjugation strategies, and applications in (pre-)clinical studies of 89Zr-based immuno-PET in oncology will be discussed, and the ongoing development of new 89ZR-labeled antibodies directed against novel tumor targets is expected to expand applications in the medical imaging.
Journal ArticleDOI
In vivo release of rhBMP-2 loaded porous calcium phosphate cement pretreated with albumin.
P.Q. Ruhé,Otto C. Boerman,Frans G. M. Russel,Antonios G. Mikos,Paul H.M. Spauwen,John A. Jansen +5 more
TL;DR: Scintigraphy of 131I-labeled rhB MP-2 provides a reliable method for longitudinal measurement of rhBMP-2 release kinetics in vivo, and it is concluded that albumin pretreatment of porous Ca-P cement does not results in relevant increase of initial release of rh BMP- 2 in vivo.
Journal Article
Synthesis and Comparison of 99mTc-Enrofloxacin and 99mTc-Ciprofloxacin
TL;DR: The study demonstrated that ( 99m)Tc-ciprofloxacin and (99m)tc-enrofl oxacin do not show preferential binding to living bacteria.
Journal ArticleDOI
Cancer Imaging and Therapy with Bispecific Antibody Pretargeting
TL;DR: The use of bispecific antibodies followed by radiolabeled peptide haptens as a new modality of selective delivery of radionuclides for the imaging and therapy of cancer is focused on.